01. Medical imaging
Leveraging the development advantages of medical imaging big data and image recognition technology, medical imaging has become the most mature field in the combination of artificial intelligence and medical in China. The editor of the battery circuit board understands that no matter from the financing situation (2018, the financing amount in the first three quarters was 2.6 billion yuan), or the top ten estimated income in 2018, the AI medical imaging industry has performed well, and there are already mature products in the areas of tuberculosis, fundus, breast cancer, and cervical cancer, but because of this field, there has been no medical case so far. AI products have obtained three types of medical device certificates. Therefore, most of the basic medical imaging products in China are in the trial stage in hospitals, and companies in this field have basically not achieved profitability.
Medical imaging, electronic medical records, guiding robots, and virtual assistants are the main application scenarios. The circuit board factory also found that most of the products are a complete set of software and hardware solutions. At present, the products are still in the polishing stage, and the service charging model may be preferred in the future.
03. Drug research and development
Domestic new drug R & D is still dominated by generic drugs and improved drugs. Therefore, compared with foreign A1 drug R & D industry, the domestic layout is relatively backward, but the business model is clear, mainly for AI companies and pharmaceutical companies to develop new drugs.
04. Health management
The editor of the circuit board learned that this field in China is not yet mature, mainly focusing on chronic disease management and maternal and child management. The business model is mainly based on health examinations paid by enterprises and individuals, and the subsequent payment model needs to be mature.
05 . Disease prediction
China mainly focuses on the field of genetic testing. Due to the existence of technical barriers, the upstream of this field is basically monopolized by foreign companies, and the downstream is mainly the hospital delivery model and the third-party testing model.